Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 10, 2005. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the Company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of share transactions rather than a financial performance report.
Material Changes
On October 7, 2005, Abacus (GSK) Trustees Limited, acting as trustee for the GlaxoSmithKline Employee Trust ("the GSK Trust"), transferred 4,415 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991. The Company was advised of these transactions on October 10, 2005.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly details a transaction notified in accordance with Disclosure Rule 3.1.4R(1)(b). The GSK Trust is identified as a discretionary trust where all current and former employees are potential beneficiaries. Three directors (Dr J-P Garnier, Dr T Yamada, and Mr J S Heslop) hold interests in the shares held by the GSK Trust in the same capacity as other employees.
Investor Verification Points
- Verify the total number of shares transferred (4,415) and the specific plan involved (SmithKline Beecham Employee Share Option Plan 1991).
- Confirm the date of the transaction (October 7, 2005) versus the date of notification to the Company (October 10, 2005).
- Review the status of the GSK Trust as a discretionary trust for employees and former employees.
- Note that this filing does not contain financial performance data for the period.